Castleark Management’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
Other funds holding KRYS
Castleark Management's KRYS Position: Q3 2026 in Review
Castleark Management increased its Krystal Biotech (KRYS) stake by 1.1% in Q3 2026, buying an estimated $58.9K and bringing the position to 16,320 shares worth $5.43M. The position accounts for 0.14% of the portfolio, ranked #150.
Castleark Management first reported a position in KRYS in Q3 2023 and has held it in 10 quarters since. The position peaked at $8.17M in Q1 2026. 442 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.
- Castleark Management held 16,320 shares of Krystal Biotech worth $5.43M as of Q3 2026.
- Castleark Management bought 170 Krystal Biotech shares in Q3 2026, an estimated $58.9K.
- Krystal Biotech made up 0.14% of Castleark Management's portfolio in Q3 2026, its #150 holding.
- Castleark Management first reported a position in Krystal Biotech in Q3 2023 and has held it in 10 quarters since.
- Castleark Management's Krystal Biotech position peaked at $8.17M in Q1 2026.
- 442 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.
Based on Castleark Management's 13F filing for Q3 2026, filed 16 Nov 2026.